CT-95 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
Do I need to stop my current medications for the CT-95 trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
How does the drug CT-95 for cancer differ from other treatments?
What data supports the effectiveness of the treatment CT-95 for cancer?
Who Is on the Research Team?
Karen Chagin, MD
Principal Investigator
Context Therapeutics Inc.
Are You a Good Fit for This Trial?
This trial is for individuals with advanced solid tumors that show Mesothelin expression, including various cancers like mesothelioma, ovarian, lung, pancreatic, and bile duct cancer. Specific eligibility criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CT-95 weekly for each 28-day cycle until disease progression, unacceptable toxicity, or decision to discontinue
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants' overall survival is monitored
What Are the Treatments Tested in This Trial?
Interventions
- CT-95
Find a Clinic Near You
Who Is Running the Clinical Trial?
Context Therapeutics Inc.
Lead Sponsor